Showing results (241-250 of 316) with videos related to

Sort By:
Pageof 32
International Journal of Radiation Oncology, Biology, Physics|July 20, 2017
PSMB8 as a Candidate Marker of Responsiveness to Preoperative Radiation Therapy in Rectal Cancer PatientsYe Jin Ha, Ka Hee Tak, Chan Wook Kim, et al.
Oncotarget|January 7, 2017
Is the pathological regression level of metastatic lymph nodes associated with oncologic outcomes following preoperative chemoradiotherapy in rectal cancer?Jung Pil Choi, Sung Joo Kim, In Ja Park, et al.
Clinical Colorectal Cancer|December 2, 2022
Pathologic Implications of Magnetic Resonance Imaging-detected Extramural Venous Invasion of Rectal CancerHyun Gu Lee, Chan Wook Kim, Jong Keon Jang, et al.
Oncotarget|September 24, 2017
Association of immunologic markers from complete blood counts with the response to preoperative chemoradiotherapy and prognosis in locally advanced rectal cancerSung Woo Jung, In Ja Park, Se Heon Oh, et al.
European Journal of Dermatology : EJD|December 15, 2012
Topical vitamin K1 may not be effective in preventing acneiform rash during cetuximab treatment in patients with metastatic colorectal cancerJae-Cheol Jo, Yong Sang Hong, Kyu-pyo Kim, et al.
Oncotarget|November 8, 2017
Peri-treatment change of anorectal function in patients with rectal cancer after preoperative chemoradiotherapyJin Sook Song, In Ja Park, Jeong Hye Kim, et al.
Oncotarget|April 13, 2017
Post-pulmonary metastasectomy prognosis after curative resection for colorectal cancerJee Yeon Kim, In Ja Park, Hyeong Ryul Kim, et al.
Medicine|August 7, 2016
Variability in the lymph node retrieval after resection of colon cancer: Influence of operative period and processJung Pil Choi, In Ja Park, Byung Cheol Lee, et al.
International Journal of Radiation Oncology, Biology, Physics|March 18, 2009
lymph node ratio as a prognostic factor in patients with stage III rectal cancer treated with total mesorectal excision followed by chemoradiotherapyYoung Seok Kim, Jong Hoon Kim, Sang Min Yoon, et al.
Oncology|September 10, 2009
The role of KRAS mutations in predicting the efficacy of cetuximab-plus-irinotecan therapy in irinotecan-refractory Korean metastatic colorectal cancer patientsByeong Seok Sohn, Tae Won Kim, Jae-Lyun Lee, et al.
Pageof 32